| FDA – 02/07/2014 | |
| Generic Name: | carbenoxolone |
|---|---|
| Trade Name: | |
| Orphan Designation: | Treatment of Huntington’s Disease |
| Orphan Designation Status: | Designated |
| FDA Orphan Approved: | Not FDA Approved for Orphan Indication |
| Sponsor: | Oxalys Pharmaceuticals |
-
-
[[Whitepaper ]] Disruptive Innovation in Rare Disease Markets
-
Choosing the Right Channel Strategy for Specialty Product Success
-
[Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies
-
[[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches
-
What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)
